Equities Analysts Issue Forecasts for CVKD FY2024 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Investment analysts at Zacks Small Cap lifted their FY2024 EPS estimates for Cadrenal Therapeutics in a research note issued to investors on Wednesday, November 20th. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings of ($7.18) per share for the year, up from their previous estimate of ($8.17). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.92) per share. Zacks Small Cap also issued estimates for Cadrenal Therapeutics’ Q4 2024 earnings at ($1.41) EPS.

Separately, HC Wainwright lifted their price target on Cadrenal Therapeutics from $3.00 to $32.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Cadrenal Therapeutics Stock Performance

Shares of NASDAQ:CVKD opened at $14.01 on Friday. The firm has a 50-day moving average price of $14.31. The company has a market cap of $23.26 million, a P/E ratio of -2.10 and a beta of 1.52. Cadrenal Therapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $32.55.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.